Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Anti-hypertension Therapeutics market. The report identifies the key trends shaping and driving the global Anti-hypertension Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anti-hypertension Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope
The report provides information on the key drivers and challenges of the Anti-hypertension Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Anti-hypertension Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Anti-hypertension Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anti-hypertension Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Anti-hypertension Therapeutics market

Reasons to buy
The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Anti-hypertension Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Anti-hypertension Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Anti-hypertension Therapeutics market landscape? - Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 ANTI-HYPERTENSION THERAPEUTICS - INTRODUCTION

2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Signs and Symptoms
2.5 Diagnosis
  2.5.1 Medical History
  2.5.2 Physical Examination
  2.5.3 Routine Diagnostic Evaluations
2.6 Pathophysiology
2.7 Treatment and Management Pattern
  2.7.1 Angiotensin II Receptor Blockers (ARB)
  2.7.2 Angiotensin Converting Enzyme (ACE) Inhibitors
  2.7.3 Diuretics
  2.7.4 Beta Blockers (BB)
  2.7.5 Calcium Channel Blockers (CCBs)
  2.7.6 Direct Renin Inhibitors (DRIs)
2.8 GlobalData Pipeline Report Guidance

3 ANTI-HYPERTENSION THERAPEUTICS - MARKET CHARACTERIZATION

3.1 Overview
3.2 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Global
3.3 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Global
3.4 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - The US
3.5 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - The US
3.6 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - France
3.7 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - France
3.8 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Germany
3.9 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Germany
3.10 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Italy
3.11 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Italy
3.12 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Spain
3.13 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Spain
3.14 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - The UK
3.15 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - The UK
3.16 Anti-Hypertension Therapeutics Market Size (2005 - 2010) - Japan
3.17 Anti-Hypertension Therapeutics Market Forecast (2010 - 2018) - Japan
3.18 Drivers and Barriers for Anti-Hypertension Therapeutics Market
  3.18.1 Drivers for the Anti-Hypertension Therapeutics Market
  3.18.2 Barriers for the Anti-Hypertension Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway

4 ANTI-HYPERTENSION THERAPEUTICS - COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Anti-Hypertension Therapeutics
  4.3.1 Diovan (valsartan)
  4.3.2 Cozaar (losartan)
  4.3.3 Vasotec (enalapril)
  4.3.4 Lotensin (benazepril)
  4.3.5 Thiazide Diuretics
  4.3.6 Loop Diuretics
  4.3.7 Toprol-XL (metoprolol succinate)
  4.3.8 Tenormin (atenolol)
  4.3.9 Norvasc (amlodipine)
  4.3.10 Tekturna (aliskiren)
4.4 Key Takeaway

5 ANTI-HYPERTENSION THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Anti-Hypertension Therapeutics Pipeline - Pipeline by Phases of Development
  5.3.1 Anti-Hypertension Therapeutics - Phase III and Regulatory Filed Clinical Pipeline
  5.3.2 Anti-Hypertension Therapeutics - Phase II Clinical Pipeline
  5.3.3 Anti-Hypertension Therapeutics - Phase I Clinical Pipeline
  5.3.4 Anti-Hypertension Therapeutics - Pre-Clinical Pipeline
  5.3.5 Technology Trends Analytic Framework
5.4 Anti-Hypertension Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.5 Anti-Hypertension Therapeutics - Drugs Under Clinical Development
5.6 Anti-Hypertension Therapeutics - Molecule Profile for Promising Drugs Under Clinical Development
  5.6.1 TAK-491
  5.6.2 EUR 1000 (Extended release propranalol)
  5.6.3 Irbesartan/Amlodipine
  5.6.4 S-474474
  5.6.5 Telmisartan + Amlodipine + Hydrochlorothiazide
5.7 Anti-Hypertension Therapeutics - Other Promising Drugs Under Clinical Development
  5.7.1 LCZ696
5.8 Key Takeaway

6 ANTI-HYPERTENSION THERAPEUTICS - CLINICAL TRIAL MAPPING

6.1 Clinical Trials by Region/Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials Mapping by Sponsors
6.5 Clinical Trials Mapping by Prominent Sponsors
6.6 Top Companies Participating in Anti-Hypertension Therapeutics Clinical Trials

7 ANTI-HYPERTENSION THERAPEUTICS - STRATEGIC ASSESSMENT

7.1 Key Events Affecting the Future Market
7.2 Implications for Future Market Competition

8 ANTI-HYPERTENSION THERAPEUTICS - FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles
  8.2.1 Takeda Pharmaceutical Company Limited
  8.2.2 Aptalis
  8.2.3 Novartis AG
  8.2.4 Sanofi
8.3 Other Companies in the Anti-Hypertension Therapeutics Market

9 ANTI-HYPERTENSION THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS

10 ANTI-HYPERTENSION THERAPEUTICS - APPENDIX

10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
  10.3.1 Coverage
  10.3.2 Secondary Research
  10.3.3 Forecasting
  10.3.4 Primary Research
  10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

LIST OF TABLES

Table 1: Classification of BP
Table 2: Recommendations for Follow-up Based on Initial BP Measurements for Adults Without Acute End-Organ Damage
Table 3: Complications of Various Types of Hypertension
Table 4: Major Risk Factors for Developing Hypertension
Table 5: Baseline Blood Tests Recommended by JNC-7
Table 6: Clinical Implications of Abnormal Laboratory Tests
Table 7: Risk Stratification of BP to Quantify Prognosis
Table 8: Major Therapeutic Classes of Anti-Hypertension Drugs
Table 9: Anti-Hypertension Therapeutics Market, Global, Revenue, ($bn), 2005 - 2010
Table 10: Anti-Hypertension Therapeutics Market, Global, Forecast ($bn), 2010 - 2018
Table 11: Anti-Hypertension Therapeutics Market, The US, Revenue ($bn), 2005 - 2010
Table 12: Anti-Hypertension Therapeutics Market, The US, Forecast ($bn), 2010 - 2018
Table 13: Anti-Hypertension Therapeutics Market, France, Revenue ($bn), 2005 - 2010
Table 14: Anti-Hypertension Therapeutics Market, France, Forecast ($bn), 2010 - 2018
Table 15: Anti-Hypertension Therapeutics Market, Germany, Revenue ($bn), 2005 - 2010
Table 16: Anti-Hypertension Therapeutics Market, Germany, Forecast ($bn), 2010 - 2018
Table 17: Anti-Hypertension Therapeutics Market, Italy, Revenue ($bn), 2005 - 2010
Table 18: Anti-Hypertension Therapeutics Market, Italy, Forecast ($bn), 2010 - 2018
Table 19: Anti-Hypertension Therapeutics Market, Spain, Revenue ($bn), 2005 - 2010
Table 20: Anti-Hypertension Therapeutics Market, Spain, Forecast ($bn), 2010 - 2018
Table 21: Anti-Hypertension Therapeutics Market, The UK, Revenue ($bn), 2005 - 2010
Table 22: Anti-Hypertension Therapeutics Market, The UK, Forecast ($bn), 2010 - 2018
Table 23: Anti-Hypertension Therapeutics Market, Japan, Revenue ($bn), 2005 - 2010
Table 24: Anti-Hypertension Therapeutics Market, Japan, Forecast ($bn), 2010 - 2018
Table 25: Anti-Hypertension Therapeutics - Phase III and Regulatory Filed Pipeline, 2011
Table 26: Anti-Hypertension Therapeutics - Phase II Clinical Pipeline, 2011
Table 27: Anti-Hypertension Therapeutics - Phase I Clinical Pipeline, 2011
Table 28: Anti-Hypertension Therapeutics - Pre-Clinical Pipeline, 2011
Table 29: Anti-Hypertension Therapeutics - Most Promising Drugs Under Clinical Development, 2010
Table 30: Anti-Hypertension Therapeutics Market, Clinical Trials by Region/Country, (Number), 2011
Table 31: Anti-Hypertension Therapeutics Market, Clinical Trials by Phase, 2011
Table 32: Anti-Hypertension Therapeutics Market, Clinical Trials by Trial Status, 2011
Table 33: Anti-Hypertension Therapeutics Market, Clinical Trials by Overall Sponsors, 2011
Table 34: Anti-Hypertension Therapeutics Market, Clinical Trials by Prominent Sponsors, 2011
Table 35: Anti-Hypertension Therapeutics Market, Companies Participating in Clinical Trials, 2011
Table 36: Takeda - Anti-Hypertension Pipeline Products, 2011
Table 37: Aptalis - Cardiovascular Pipeline Products, 2011
Table 38: Novartis AG - Anti-Hypertension Pipeline Products, 2011
Table 39: Sanofi - Anti-Hypertension Pipeline Products, 2011
Table 40: Other Companies in the Anti-Hypertension Therapeutics Market
Table 41: Anti-Hypertension Therapeutics Market, Global, Deals, 2011

LIST OF FIGURES

Figure 1: Stages of BP
Figure 2: Classification of BP and Types of Hypertension
Figure 3: Common Factors Leading to Secondary Hypertension
Figure 4: Pathophysiology of Essential Hypertension
Figure 5: Renin Angiotensin-Aldosterone System (RAAS) for Regulation of High BP
Figure 6: Treatment Algorithm for Hypertension
Figure 7: Anti-Hypertension Therapeutics Market, Global, Revenue ($bn), 2005 - 2010
Figure 8: Anti-Hypertension Therapeutics Market, Global, Forecast ($bn), 2010 - 2018
Figure 9: Anti-Hypertension Therapeutics Market, The US, Revenue ($bn), 2005 - 2010
Figure 10: Anti-Hypertension Therapeutics Market, The US, Forecast ($bn), 2010 - 2018
Figure 11: Anti-Hypertension Therapeutics Market, France, Revenue ($bn), 2005 - 2010
Figure 12: Anti-Hypertension Therapeutics Market, France, Forecast ($bn), 2010 - 2018
Figure 13: Anti-Hypertension Therapeutics Market, Germany, Revenue ($bn), 2005 - 2010
Figure 14: Anti-Hypertension Therapeutics Market, Germany, Forecast ($bn), 2010 - 2018
Figure 15: Anti-Hypertension Therapeutics Market, Italy, Revenue ($bn), 2005 - 2010
Figure 16: Anti-Hypertension Therapeutics Market, Italy, Forecast ($bn), 2010 - 2018
Figure 17: Anti-Hypertension Therapeutics Market, Spain, Revenue ($bn), 2005 - 2010
Figure 18: Anti-Hypertension Therapeutics Market, Spain, Forecast ($bn), 2010 - 2018
Figure 19: Anti-Hypertension Therapeutics Market, The UK, Revenue ($bn), 2005 - 2010
Figure 20: Anti-Hypertension Therapeutics Market, The UK, Forecast ($bn), 2010 - 2018
Figure 21: Anti-Hypertension Therapeutics Market, Japan, Revenue ($bn), 2005 - 2010
Figure 22: Anti-Hypertension Therapeutics Market, Japan, Forecast ($bn), 2010 - 2018
Figure 23: Opportunity and Unmet Need in the Anti-Hypertension Therapeutics Market, 2011
Figure 24: Strategic Competitor Assessment of the Marketed Products for Anti-Hypertension, 2011
Figure 25: Anti-Hypertension Therapeutics Pipeline by Phase of Development, 2011
Figure 26: Anti-Hypertension Therapeutics - Technology Trends Analytics Framework
Figure 27: Anti-Hypertension Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 28: Anti-Hypertension Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 29: Anti-Hypertension Therapeutics Market, Clinical Trials by Region/Country, (Number), 2011
Figure 30: Anti-Hypertension Therapeutics Market, Clinical Pipeline by Phase, (%), 2011
Figure 31: Anti-Hypertension Therapeutics Market, Clinical Trials by Trial Status, (%), 2011
Figure 32: Anti-Hypertension Therapeutics Market, Clinical Trials by Overall Sponsors, (%), 2011
Figure 33: Anti-Hypertension Therapeutics Market, Clinical Trials by Prominent Sponsors, (%), 2011
Figure 34: Anti-Hypertension Therapeutics Market, Companies Participating in Clinical Trials, 2011
Figure 35: Anti-Hypertension Therapeutics, Global, Key Events Impacting the Future Market, 2011
Figure 36: Implications for Future Market Competition in the Anti-Hypertension Therapeutics Market, 2011
Figure 37: Anti-Hypertension Therapeutics Market - Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Takeda Pharmaceutical Company Limited
Aptalis
Novartis AG
Sanofi Skip to top